Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 4/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL29164016 | 0.95 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDGAAHSD17B10 | |
| Trifluoroacetic Acid SCHEMBL25305646 | 0.90 | SOS1 (0.42) | ALDH1A1KDM4EHPGDGAAHSD17B10 | |
| SCHEMBL28381224 | 0.84 | GAA (0.50) | ALDH1A1KDM4EHPGDGAAMAPT | |
| SCHEMBL25360368 | 0.82 | KDM4E (0.44) | ALDH1A1KDM4EHPGDGAAHSD17B10 | |
| SCHEMBL29824155 | 0.82 | KDM4E (0.44) | ALDH1A1KDM4EHPGDGAAHSD17B10 | |
| SCHEMBL29164014 | 0.81 | KDM4E (0.41) | ALDH1A1KDM4EHPGDGAAHSD17B10 | |
| SCHEMBL21001745 | 0.81 | GAA (0.41) | ALDH1A1KDM4EHPGDGAAMAPT | |
| SCHEMBL31692851 | 0.81 | IKBKB (0.46) | ALDH1A1KDM4EHPGDGAAHSD17B10 | |
| SCHEMBL30006976 | 0.81 | GABRP (0.46) | ALDH1A1KDM4EHSD17B10GLAKMT2A | |
| SCHEMBL3300500 | 0.81 | GABRP (0.46) | ALDH1A1KDM4EHSD17B10GLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240247015-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-07-25 | — | — | US | disclosed |
| EP-4322962-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2024-02-21 | — | — | EP | disclosed |
| CN-117500507-A | Phosphorus derivatives as novel SOS1 inhibitors | 拜耳公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230357239-A1 | PYRIDO[2,3-D]PYRIMIDIN-4-AMINES AS SOS1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| WO-2023151640-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| EP-4214204-A1 | PYRIDO[2,3-D]PYRIMIDIN-4-AMINES AS SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-07-26 | — | — | EP | disclosed |
| CN-116323623-A | Pyrido [2,3-d ] pyrimidin-4-amines as SOS1 inhibitors | 拜耳公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022219035-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-20 | — | — | WO | disclosed |
| EP-4074317-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | Bayer AG (DE) | 2022-10-19 | — | — | EP | disclosed |
| WO-2022058344-A1 | PYRIDO[2,3-D]PYRIMIDIN-4-AMINES AS SOS1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-03-24 | — | — | WO | disclosed |
| US-20200131180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM2, CHRM4 | ALDH1A1 3782/4885KDM4E 1530/4885HPGD 3627/4885 |
| US-20230357239-A1 | PYRIDO[2,3-D]PYRIMIDIN-4-AMINES AS SOS1 INHIBITORS | SOS1, PPM1D, SOS2 | ALDH1A1 1836/4885KDM4E 3648/4885HPGD 2247/4885 |
| US-20240247015-A1 | PHOSPHORUS DERIVATIVES AS NOVEL SOS1 INHIBITORS | SOST, PPM1D, SOS1 | ALDH1A1 4644/4885KDM4E 4080/4885HPGD 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.